Unknown

Dataset Information

0

Genome-wide association study of leukotriene modifier response in asthma.


ABSTRACT: Heterogeneous therapeutic responses to leukotriene modifiers (LTMs) are likely due to variation in patient genetics. Although prior candidate gene studies implicated multiple pharmacogenetic loci, to date, no genome-wide association study (GWAS) of LTM response was reported. In this study, DNA and phenotypic information from two placebo-controlled trials (total N=526) of zileuton response were interrogated. Using a gene-environment (G × E) GWAS model, we evaluated 12-week change in forced expiratory volume in 1 second (ΔFEV1) following LTM treatment. The top 50 single-nucleotide polymorphism associations were replicated in an independent zileuton treatment cohort, and two additional cohorts of montelukast response. In a combined analysis (discovery+replication), rs12436663 in MRPP3 achieved genome-wide significance (P=6.28 × 10(-08)); homozygous rs12436663 carriers showed a significant reduction in mean ΔFEV1 following zileuton treatment. In addition, rs517020 in GLT1D1 was associated with worsening responses to both montelukast and zileuton (combined P=1.25 × 10(-07)). These findings implicate previously unreported loci in determining therapeutic responsiveness to LTMs.

SUBMITTER: Dahlin A 

PROVIDER: S-EPMC4668236 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| PRJNA75657 | ENA
| S-EPMC7054824 | biostudies-literature
| S-EPMC9671132 | biostudies-literature
| S-EPMC4470685 | biostudies-literature
| S-EPMC6325805 | biostudies-other
| S-EPMC8606614 | biostudies-literature
| S-EPMC3268734 | biostudies-literature
| S-EPMC6414286 | biostudies-literature
| S-EPMC3606015 | biostudies-literature
| S-EPMC8122045 | biostudies-literature